Academic Content and Language Evaluation of This Article
Academic Rules and Norms of This Article
Citation of this article
Corresponding Author of This Article
Research Domain of This Article
Article-Type of This Article
Open-Access Policy of This Article
Times Cited Counts in Google of This Article
Number of Hits and Downloads for This Article
- Total Article Views (7510)
All Articles published online
|
Featured Article
|
Publishing Process of This Article
|
Feb 15, 2022 (publication date) through Dec 21, 2024
Times Cited of This Article
Journal Information of This Article
Publication Name
World Journal of Diabetes
ISSN
1948-9358
Publisher of This Article
Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
| For: | Florentin M, Kostapanos MS, Papazafiropoulou AK. Role of dipeptidyl peptidase 4 inhibitors in the new era of antidiabetic treatment. World J Diabetes 2022; 13(2): 85-96 [PMID: 35211246 DOI: 10.4239/wjd.v13.i2.85] |
|---|---|
| URL: | https://www.wjgnet.com/1948-9358/full/v13/i2/85.htm |
| Number | Citing Articles |
| 1 |
Shinichiro Shirabe, Katsuya Yamazaki, Mariko Oishi, Keiko Arai, Noriharu Yagi, Manaka Sato, Masakazu Takeuchi, Takahito Kai, Hiroshi Maegawa. Changes in prescription patterns and doses of oral antidiabetic drugs in Japanese patients with type 2 diabetes (JDDM70). Journal of Diabetes Investigation 2023; 14(1): 75 doi: 10.1111/jdi.13922
|
| 2 |
Albert Joseph Sulangi, Sarah E Lyons, Amy A Abdou, Hemangi Patel, Deepika Nagliya, Eileen Joseph, Carmel Joseph, Divya Kumar, Shivani Patel, Isha Jinwala, Mayur S Parmar. Exploring the Therapeutic Potential of DPP4 Inhibitors in Alzheimer's Disease: Molecular Insight and Clinical Outcome. Cureus 2024; doi: 10.7759/cureus.72648
|
| 3 |
Eiji Kobayashi, Yusuke Kamihara, Miho Arai, Akinori Wada, Shohei Kikuchi, Ryo Hatano, Noriaki Iwao, Takeshi Susukida, Tatsuhiko Ozawa, Yuichi Adachi, Hiroyuki Kishi, Nam H. Dang, Taketo Yamada, Yoshihiro Hayakawa, Chikao Morimoto, Tsutomu Sato. Development of a Novel CD26-Targeted Chimeric Antigen Receptor T-Cell Therapy for CD26-Expressing T-Cell Malignancies. Cells 2023; 12(16): 2059 doi: 10.3390/cells12162059
|
| 4 |
Peng Ning, Xiaobo Jiang, Jing Yang, Jiaxing Zhang, Fan Yang, Hongyi Cao. Mitophagy: A potential therapeutic target for insulin resistance. Frontiers in Physiology 2022; 13 doi: 10.3389/fphys.2022.957968
|
| 5 |
Juan Gao, Erwin Adams, Zhengjin Jiang, Ann Van Schepdael. A versatile and automatic on-line screening method: Transverse diffusion of laminar flow profiles-based capillary electrophoresis for exploring PTP1B inhibitors in natural products. Journal of Chromatography A 2025; 1741: 465607 doi: 10.1016/j.chroma.2024.465607
|
| 6 |
Miruna-Maria Apetroaei, Persefoni Fragkiadaki, Bruno Ștefan Velescu, Stella Baliou, Elisavet Renieri, Cristina Elena Dinu-Pirvu, Doina Drăgănescu, Ana Maria Vlăsceanu, Marina Ionela (Ilie) Nedea, Denisa Ioana Udeanu, Anca Oana Docea, Artistidis Tsatsakis, Andreea Letiția Arsene. Pharmacotherapeutic Considerations on Telomere Biology: The Positive Effect of Pharmacologically Active Substances on Telomere Length. International Journal of Molecular Sciences 2024; 25(14): 7694 doi: 10.3390/ijms25147694
|
| 7 |
Bushra Mobeen, Muhammad Shah, Hafiz Muzzammel Rehman, Muhammad Saeed Jan, Umer Rashid. Discovery of the selective and nanomolar inhibitor of DPP-4 more potent than sitagliptin by structure-guided rational design. European Journal of Medicinal Chemistry 2024; 279: 116834 doi: 10.1016/j.ejmech.2024.116834
|
| 8 |
Masaaki Yoshida, Taiki Kokubun, Kota Sato, Satoru Tsuda, Yu Yokoyama, Noriko Himori, Toru Nakazawa. DPP-4 Inhibitors Attenuate Fibrosis After Glaucoma Filtering Surgery by Suppressing the TGF-β/Smad Signaling Pathway. Investigative Opthalmology & Visual Science 2023; 64(10): 2 doi: 10.1167/iovs.64.10.2
|
| 9 |
A.B.M. Kamrul-Hasan, Deep Dutta, Lakshmi Nagendra, Meha Sharma, Shinjan Patra, Saptarshi Bhattacharya. Role of anagliptin, a dipeptidyl peptidase-4 inhibitor, in managing type 2 diabetes: A systematic review and meta-analysis. Medicine 2024; 103(28): e38870 doi: 10.1097/MD.0000000000038870
|
| 10 |
Yarini Arrebola Sánchez, Fabiola Almeida García, Daniel Ojeda del Sol, Mario E. Valdés-Tresanco, Carlos David Ortiz, Belinda Sánchez Ramírez, Isel Pascual Alonso. Dipeptidyl peptidase IV: a multifunctional enzyme with implications in several pathologies including cancer. Physical Sciences Reviews 2024; 9(8): 2541 doi: 10.1515/psr-2022-0288
|
| 11 |
Assessment of Factors Affecting Therapeutic Response of the DPP-4 Inhibitor Sitagliptin in A Sample of Iraqi Type 2 Diabetic Patients. Al Mustansiriyah Journal of Pharmaceutical Sciences 2024; 24(3): 311 doi: 10.32947/ajps.v24i3.1082
|
| 12 |
Kyoko Oura, Asahiro Morishita, Joji Tani, Tsutomu Masaki. Antitumor Effects and Mechanisms of Metabolic Syndrome Medications on Hepatocellular Carcinoma. Journal of Hepatocellular Carcinoma 2022; : 1279 doi: 10.2147/JHC.S392051
|
| 13 |
Ritika Sindhwani, Kundan Singh Bora, Subhajit Hazra. The dual challenge of diabesity: pathophysiology, management, and future directions. Naunyn-Schmiedeberg's Archives of Pharmacology 2024; doi: 10.1007/s00210-024-03713-4
|
| 14 |
Sanjay Kalra, Saptarshi Bhattacharya, A Dhingra, Sambit Das, Nitin Kapoor, Shehla Shaikh, Vivek Kolapkar, R V Lokesh Kumar, Kamlesh Patel, Rahul Kotwal. Expert Consensus on Dipeptidyl Peptidase-4 Inhibitor-Based Therapies in the Modern Era of Type 2 Diabetes Mellitus Management in India. Cureus 2024; doi: 10.7759/cureus.61766
|
| 15 |
Nancy S. Elbarbary, Eman A. Ismail, Manal H. El-Hamamsy, Marwa Z. Ibrahim, Amal A. Elkholy. The DPP-4 inhibitor sitagliptin improves glycaemic control and early-stage diabetic nephropathy in adolescents with type 1 diabetes using the MiniMed 780G advanced hybrid closed-loop system: a randomised controlled trial. Diabetologia 2024; 67(12): 2637 doi: 10.1007/s00125-024-06265-7
|
| 16 |
Rajani Kanth Gudipati, Dimos Gaidatzis, Jan Seebacher, Sandra Muehlhaeusser, Georg Kempf, Simone Cavadini, Daniel Hess, Charlotte Soneson, Helge Großhans. Deep quantification of substrate turnover defines protease subsite cooperativity. Molecular Systems Biology 2024; 20(12): 1303 doi: 10.1038/s44320-024-00071-4
|
| 17 |
Jennifer Okemah, Sola Neunie, Alexander Noble, Carol Wysham. Impact on Knowledge, Competence, and Performance of a Faculty-Led Web-Based Educational Activity for Type 2 Diabetes and Obesity: Questionnaire Study Among Health Care Professionals and Analysis of Anonymized Patient Records. JMIR Formative Research 2023; 7: e49115 doi: 10.2196/49115
|
| 18 |
Swetha R Reghunath, Ashna Chackochan, Girish Thunga, Dinesh U Acharya, Kaniyoor Nagri Shivashankara, Attur Ravindra Prabhu, Leelavathi D Acharya. Prevalence and Predictors of Adverse Events Associated With Dipeptidyl Peptidase-4 (DPP-4) Inhibitors in Type 2 Diabetic Patients: A Cross-sectional Study. Clinical Medicine Insights: Endocrinology and Diabetes 2024; 17 doi: 10.1177/11795514241288645
|
| 19 |
Fen Zhuge, Liujie Zheng, Yuxiang Pan, Liyang Ni, Zhengwei Fu, Junping Shi, Yinhua Ni. DPP-4 inhibition by linagliptin ameliorates age-related mild cognitive impairment by regulating microglia polarization in mice. Experimental Neurology 2024; 373: 114689 doi: 10.1016/j.expneurol.2024.114689
|
| 20 |
A.B.M. Kamrul-Hasan, Muhammad Shah Alam, Samir Kumar Talukder, Deep Dutta, Shahjada Selim. Efficacy and Safety of Omarigliptin, a Novel Once-Weekly Dipeptidyl Peptidase-4 Inhibitor, in Type 2 Diabetes Mellitus: A Systematic Review and Meta-Analysis. Endocrinology and Metabolism 2024; 39(1): 109 doi: 10.3803/EnM.2023.1839
|
| 21 |
Awadhesh Kumar Singh, Ritu Singh. Relook at DPP-4 inhibitors in the era of SGLT-2 inhibitors. World Journal of Diabetes 2022; 13(6): 466-470 doi: 10.4239/wjd.v13.i6.466
|
| 22 |
György Jermendy, Zoltán Kiss, György Rokszin, Zsolt Abonyi-Tóth, Csaba Lengyel, Péter Kempler, István Wittmann. Changing Patterns of Antihyperglycaemic Treatment among Patients with Type 2 Diabetes in Hungary between 2015 and 2020—Nationwide Data from a Register-Based Analysis. Medicina 2022; 58(10): 1382 doi: 10.3390/medicina58101382
|
| 23 |
A.B.M. Kamrul-Hasan, Muhammad Shah Alam, Samir Kumar Talukder, Deep Dutta, Shahjada Selim. Efficacy and Safety of Omarigliptin, a Novel Once-Weekly Dipeptidyl Peptidase-4 Inhibitor, in Type 2 Diabetes Mellitus: A Systematic Review and Meta-Analysis. Endocrinology and Metabolism 2024; 39(1): 109 doi: 10.3803/EnM.2024.1839
|
| 24 |
Aleksandra Pilszyk, Magdalena Niebrzydowska, Zuzanna Pilszyk, Magdalena Wierzchowska-Opoka, Żaneta Kimber-Trojnar. Incretins as a Potential Treatment Option for Gestational Diabetes Mellitus. International Journal of Molecular Sciences 2022; 23(17): 10101 doi: 10.3390/ijms231710101
|